22 December 2021
EFPIA Japan

EFPIA Japan Appoints Dr. Takeo Morooka as Director General
TOKYO – 22 December 2021 – EFPIA Japan announced today that Dr. Takeo Morooka has been
appointed Director General of EFPIA Japan, effective 15 December 2021. Former Director
General Yasuhiro Nishimi continues to serve as Chair of Pricing and Economics Committee.
Upon the appointment, Dr. Morooka says, "The pharmaceutical industry has had a paramountrole in fighting against the pandemic by leveraging years of investment in vaccine and therapeutictechnology platforms. We now recognize the power of science and innovation and how critical
public-private-academia collaboration is in addressing healthcare challenges. We believe thatboth public and private stakeholders have an important role to play in strengthening ourhealthcare systems and fostering innovation. To this end, I look forward to working closely with
our stakeholders.”
EFPIA Japan Chair Iwaya says, “It is a pleasure to have the Director General with experience inboth the industry and government and as a clinician onboard to EFPIA Japan. With the addition ofDr. Morooka, we will further enhance our initiatives as an industry group and contribute todiscussions to improve healthcare systems ultimately to serve the needs of healthcare andpatients in Japan.”
After graduating from Kyoto University School of Medicine in 1994, Dr. Morooka served as plasticsurgeon at Kobe City General Hospital and other hospitals. He joined the Ministry of Health andWelfare in 1998, graduated from the Harvard School of Public Health in 2001, and was seconded
to the World Health Organization Headquarters in Geneva in 2002 as External Affairs Officer.
After the lift of his secondment from the Ministry of Health, Labour and Welfare in 2005, heserved as Medical Officer at the WHO Headquarters. He had worked at International University ofHealth and Welfare since 2007, Covidien Japan since 2010, and MSD K.K. since 2015 as seniormanagement.

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870

About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceuticalcompanies operating in Japan. In 2020, combined sales from the member companies accountedfor roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents thepharmaceutical industry operating in Europe. Through its direct membership of 36 national
associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies
committed to researching, developing and bringing new medicines to improve health and qualityof life around the world.

Contact:Yuko Kidoguchi
EFPIA Japan Messaging & Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870